Roche’s obesity shot posts decent weight loss in mid-stage test, heads to Phase 3

Roche’s most advanced obesity drug allowed patients in a Phase 2 trial who took it for nearly a year to lose 18.3% of their weight after correcting for placebo, the Swiss pharma